As planned, US drugmaker Pfizer and German biotech BioNTech filed an Emergency Use Authorization (EUA) request with the US Food and Drug Administration (FDA) for their mRNA-based Covid-19 vaccine candidate BNT162b2 on Nov. 20.
UK specialty chemical company Croda International has agreed to supply Pfizer with novel excipients used to make the drugmaker’s Covid-19 vaccine candidate. The contract, which is for a term of five years, enables Croda to initially supply four component excipients for the first three years of the agreement.
US drugmaker Pfizer and its German development partner BioNTech have reached a final agreement with the European Commission to supply 200 million doses of their mRNA-based Covid19 vaccine candidate to the EU’s member states at an undisclosed price.
German CDMO Rentschler Biopharma has reached agreement with Pfizer and BioNTech to handle the downstream purification process for the partnership’s mRNA-based COVID-19 vaccine. No price tag was disclosed for the deal that also calls for the CDMO to handle small-batch manufacturing for a range of BioNTech's other mRNA clinical-stage projects.
Only a few weeks ago, the race to bring Covid-19 vaccines was in high gear. Now some think the pace should be slower, amid AstraZeneca’s much commentated adverse event during its UK Phase 3 trial and US president Donald Trump’s haste to have a vaccine ready for deployment before the Nov.3 US elections.
The Covid-19 initiative of the German Federal Ministry of Education and Research (BMBF) has awarded a milestone-based grant of up to €375 million for BioNTech, the Mainz, Germany-based biotech, to support its efforts to develop a commercially available vaccine against the virus.
With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a doubting public could shun inoculation.
French biotech Domain Therapeutics, which specializes in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology and rare diseases, has signed a collaboration agreement with US pharma giant Pfizer to profile downstream signaling pathways of a set of GPCRs potentially involved across multiple therapeutic areas.
After teaming up with Germany’s BioNTech to develop a vaccine for Covid-19, US drugs giant Pfizer is joining US Gilead Sciences on the therapeutic side. The biopharma company’s antiviral remdesivir is currently favored as a treatment for the novel coronavirus.
The Covid-19 vaccine partnership of Germany’s BioNTech and US drugs giant Pfizer inked its third supply pact in a week on Jul. 31. This deal, with the Japanese Ministry of Health, Labor and Welfare (MHLW), follows separate agreements with the US and UK signed in the two preceding days.
European officials recently began talking to companies developing Covid-19 vaccines about supplying the EU’s 27 member states, in hope that none would fall behind bigger markets such as the US, which began making exclusive deals early on. Now Reuters suggests the talks may have hit a snag.
The world’s governments are signing vaccine supply pacts fast and furiously now, as the world continues to hope an effective prevention against Covid-19 will be found soon. Days after signing on with the UK government, German biotech BioNTech – working with American drugs giant Pfizer – has inked a deal with the US and is reportedly also talking to the EU.
To save manufacturing space for its growing vaccines plans, Pfizer has said it will outsource production of some of its pharmaceutical portfolio. The work is planned to be shared out with a network of 200 contractors in the US and Europe.
